Can we win the war on obesity with pharmacotherapy?

Gotthardt, J; Bello, Nicholas T.

doi:10.1080/17512433.2016.1232164

Cited by 10 publications

(23 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Buproprion alone is indicated for depression and smoking cessation and, notably, has a black box warning for suicidal ideation. 25 However, the combination medication of naltrexone/bupropion is not approved for these conditions. Importantly, the side effects of increased blood pressure and heart rate can make it challenging to prescribe this medication to patients with significant cardiovascular disease.…”

Section: Orlistatmentioning

confidence: 99%

“…23 In 2016, a once-daily ER form of Belviq TM was approved in the form of 20 mg daily. 25 Typical side effects reported with lorcaserin include headache, nausea, dizziness, dry mouth, constipation, fatigue, hypoglycemia, back pain, and cough. 23 The effects of lorcaserin on weight were studied in two randomized, double-blind, placebo-controlled phase III trials known as BLOOM and BLOSSOM.…”

Section: Orlistatmentioning

confidence: 99%

“…Topiramate is a component of the weight loss medication phentermine/topiramate ER approved for the chronic management of obesity, and is a known teratogen. 25 Hence, a contraceptive plan needs to be agreed upon and arranged before prescribing this medication. 7 The 2015 Endocrine Society Guidelines recommend oral contraceptive pills rather than injectable medications.…”

Section: Contraceptive Planningmentioning

confidence: 99%

“…It acts centrally as a selective 5-hydroxytryptamine (5-HT) 2C receptor agonist and is a DEA schedule IV controlled medication. 7,25 Weight loss is achieved by decreasing food intake caused by increased satiety through activation of anorexigenic pro-opiomelanocortin neurons in the hypothalamus. 23 In 2016, a once-daily ER form of Belviq TM was approved in the form of 20 mg daily.…”

Section: Orlistatmentioning

confidence: 99%

“…24 Phentermine HCl is a Drug Enforcement Agency (DEA) schedule IV controlled substance because it is an amphetamine analog. 25 Common prescription of this drug involves doses between 15.0 and 37.5 mg oral (PO) once daily in the morning. Dosing should be tailored to the needs of the patient, because some patients may respond to partial doses, such as one quarter tablet (9.375 mg) or one half tablet (18.75 mg).…”

Section: Phentermine Hclmentioning

confidence: 99%

See 4 more Smart Citations

Updates on obesity pharmacotherapy

Velazquez

Apovian

2018

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Obesity is a chronic, relapsing disease that necessitates a multidisciplinary approach to management. Behavioral changes are the foundation to management, but adjunctive therapy is often warranted, including pharmacologic therapies and/or bariatric surgery. Until recently, treatment options included only short-term therapy (ࣘ12 weeks), and paths beyond that schedule were challenging, as knowledge of the biology of obesity was lacking. With increased recognition of obesity as a chronic, complex medical disease, newer agents have been approved as long-term therapy, and the cornerstone of treatment is chronic behavior and lifestyle change. In the last decade, the Food and Drug Administration (FDA) has approved several new weight loss medications for the chronic management of obesity. In this review paper, we provide the latest updates on obesity pharmacotherapy. The main areas we will cover include (1) pharmacological management of obesity, (2) a review of FDA-approved weight loss medications, (3) comanagement of obesity and its metabolic sequelae (type 2 diabetes mellitus, hypertension, and dyslipidemia), and (4) obesity-centric prescribing for mental illness, neurological disorders, and contraceptive planning.

show abstract

Section: Orlistatmentioning

confidence: 99%

Section: Orlistatmentioning

confidence: 99%

Section: Contraceptive Planningmentioning

confidence: 99%

Section: Orlistatmentioning

confidence: 99%

Section: Phentermine Hclmentioning

confidence: 99%

See 3 more Smart Citations

Updates on obesity pharmacotherapy

Velazquez

Apovian

2018

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

A review on the potential use of natural products in overweight and obesity

Zhang

Wang

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

With the increase in unhealthy lifestyles, obesity is increasingly common, which could cause many metabolic diseases. In recent research, natural product extracts have shown tremendous potential antiobesity effects via different mechanisms. In this review, we focused on widely adopted extraction methods, bioactive ingredients types, and antiobesity mechanisms of natural product extracts in the recent reports. The extraction methods include solid-liquid extraction, microwave-assisted extractions, and supercritical fluid extraction. Moreover, the bioactive ingredients identified in natural product extracts are phenolic compounds, oligosaccharides, polysaccharides, and terpenoids. These exert antiobesity effects through multiple mechanisms, including suppressing the appetite, increasing energy expenditure, inhibiting enzyme activity, modulating lipid homeostasis and adipocyte lifecycle, reducing oxidative and inflammation, and improving intestinal bacteria. However, the antiobesity effects of natural products require further evaluation. Furthermore, the improvement of the bioavailability and effective and safe human dose of these bioactive ingredients should be the focus of future work.

show abstract